DDInter458 DDInter1950
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label]. Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving genetic material into the following structural and nonstructural proteins required for assembly into mature virus: NS3, NS4A, NS4B, NS5A, and NS5B . By inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as voxilaprevir. Voxilaprevir has been available since July 2017 in a fixed dose combination product with [sofosbuvir] and [velpatasvir] as the commercially available product Vosevi. Vosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection [FDA Label]. Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor . Prior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection.
Cyclosporine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxilaprevir
Cyclosporine {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxilaprevir
Cyclosporine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may lead to a major life threatening interaction when taken with {v} Voxilaprevir
Cyclosporine {u} (Compound) downregulates {v} (Gene) PROS1
PROS1 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxilaprevir
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC7A11
SLC7A11 {u} (Gene) is bound by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may lead to a major life threatening interaction when taken with {v} Voxilaprevir
Cyclosporine {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxilaprevir
Cyclosporine {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may lead to a major life threatening interaction when taken with {v} Voxilaprevir
Cyclosporine {u} (Compound) downregulates {v} (Gene) ZWINT
ZWINT {u} (Gene) is downregulated by {v} (Compound) Afatinib
Afatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxilaprevir
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may lead to a major life threatening interaction when taken with {v} Voxilaprevir
Cyclosporine {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may lead to a major life threatening interaction when taken with {v} Voxilaprevir
Cyclosporine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Voxilaprevir
Cyclosporine (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Voxilaprevir
Cyclosporine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Rosuvastatin (Compound) and Rosuvastatin may lead to a major life threatening interaction when taken with Voxilaprevir
Cyclosporine (Compound) downregulates PROS1 (Gene) and PROS1 (Gene) is upregulated by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Voxilaprevir
Cyclosporine (Compound) upregulates SLC7A11 (Gene) and SLC7A11 (Gene) is bound by Rosuvastatin (Compound) and Rosuvastatin may lead to a major life threatening interaction when taken with Voxilaprevir
Cyclosporine (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is downregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Voxilaprevir
Cyclosporine (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Rosuvastatin (Compound) and Rosuvastatin may lead to a major life threatening interaction when taken with Voxilaprevir
Cyclosporine (Compound) downregulates ZWINT (Gene) and ZWINT (Gene) is downregulated by Afatinib (Compound) and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Voxilaprevir
Cyclosporine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Rosuvastatin (Compound) and Rosuvastatin may lead to a major life threatening interaction when taken with Voxilaprevir
Cyclosporine (Compound) upregulates MYC (Gene) and MYC (Gene) is downregulated by Rosuvastatin (Compound) and Rosuvastatin may lead to a major life threatening interaction when taken with Voxilaprevir